Results of the study are published in the February 2008 issue of Clinical and Vaccine Immunology. The study is the first to demonstrate protective immunity against smallpox using a vaccine with inactivated virus, said Baker.
The data are the latest in a series of preclinical vaccine studies that validate NanoBio's patented nanoemulsion platform, a suspension of oil, water, alcohol and antimicrobial surfactant together with antigens from specific pathogens. The nasally delivered vaccines easily penetrate mucous membranes, where dendritic cells engulf the antigen and immediately present it to the immune system.
This rapid awakening of the immune system via mucous membranes negates the need for inflammatory stimulants used in traditional injected vaccines, which can cause pain and swelling at the site of vaccination, said Baker.
Animal studies indicate that NanoBio's vaccines quickly trigger robust immunity -- without adverse effects -- against a wide array of viruses and bacteria, including influenza, hepatitis B, RSV, anthrax and HIV.
A study to be published this month in the journal AIDS Research and Human Retroviruses demonstrates that their HIV vaccine produces both mucosal immunity as well as systemic immunity -- the immune system's long-term memory that enables it to recognize and combat future infections.
Both types of immunity are critically important, but developing mucosal immunity is particularly valuable in combating sexually transmitted diseases because they enter the body through mucous membranes, added Baker. Vaccines that are delivered to one mucosal surface, such as inside the nose, build immunity at distant mucosal surfaces as well.
"When you present an infection on one mucosal surface, the immune cells
that are recruited at that surface also traffic throughout all the mucosal
surfaces," Baker said. "Our HIV study suggests that the nanoemulsion should
be evaluated as a mu
|SOURCE NanoBio Corporation|
Copyright©2008 PR Newswire.
All rights reserved